Although PD-L1 in tumor tissue is an indicator authorized by United States Food and Drug Administration (FDA), the expression pattern of PD-L1 on tumor cells alone is not sufficient to accurately predict tumor response to anti-PD-1/PD-L1 therapy. Here, CD274 is linked to neoplasm.